

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

CLASS I & II IgM HLA ANTIBODY SPECIFICITY ANALYSIS OF 306-310/2018

DESPATCHED ON 13 NOVEMBER 2018

Lab no.	306/2018 IgM antibodies detected			307/2018 IgM antibodies detected			308/2018 IgM antibodies detected			309/2018 IgM antibodies detected			310/2018 IgM antibodies detected		
	Class I	Class II	Tech.	Class I	Class II	Tech.	Class I	Class II	Tech.	Class I	Class II	Tech.	Class I	Class II	Tech.
20	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	Cw4	ND	CDC
38	ND	ND	ND	ND	ND	ND	ND	DR11, DR12, DR13, DQ5, DQ6	LS2A01	ND	ND	ND	ND	ND	ND
42	ND	ND	CDC	ND	ND	CDC	ND	ND	CDC	ND	ND	CDC	ND	ND	CDC
162	A32	DQ7, DQA 0302, DP14	LS1A04, LS2A01	ND	DQ2	LS1A04, LS2A01	A3, A1102, A25, A26, A32, A34, A43, A66, A74, B44, B45, B76, Cw6, Cw7, Cw8, Cw12, Cw15	DR8, DR103, DR11, DR12, DR13, DR14, DR17, DR18, DR52, DR53, DQ5, DQ6, DP19, DQA0303, DQA0501	LS1A04, LS2A01	B73	ND	LS1A04, LS2A01	A3401, B46, B63, B73, Cw4, Cw7, Cw8, Cw9, Cw10, Cw12, Cw16, Cw17	ND	LS1A04, LS2A01
194	ND	ND	CDC	ND	ND	CDC	ND	ND	CDC	ND	ND	CDC	ND	ND	CDC

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

CDC % PRA OF 306-310/2018

DESPATCHED ON 13 NOVEMBER 2018

Lab no.	T-cell CDC % PRA	B-cell CDC % PRA	PBL CDC % PRA	306/2018			CDC Specificities Detected	307/2018			CDC Specificities Detected	308/2018			CDC Specificities Detected	309/2018			CDC Specificities Detected	310/2018			CDC Specificities Detected
				T-cell	B-cell	PBL		T-cell	B-cell	PBL		T-cell	B-cell	PBL		T-cell	B-cell	PBL		T-cell	B-cell	PBL	
20	NT	42	NT	NT	9.5	NT	NAD	NT	30.9	NT	DR17	NT	78	NT	DQ1, A26, ?DR11	NT	4.7	NT	NAD	NT	42.8	NT	Cw4, Cw2
28							NAD				NAD				A25, A26				NAD				Cannot exclude B39
42	NT	NT	40	NT	NT	0	NAD	NT	NT	0	NAD	NT	NT	40	A25, A26, A34, A66	NT	NT	0	NAD	NT	NT	0	NAD
194	NT	NT	40	NT	NT	0	NAD	NT	NT	0	NAD	NT	NT	72	A25, A26, A66, A34 (A10)	NT	NT	0	NAD	NT	NT	0	NAD
206	NT	NT	30	NT	NT	0	NAD	NT	NT	0	NAD	NT	NT	20	A25, A26, A66 IgG	NT	NT	0	NAD	NT	NT	10	Non HLA IgM

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

SOLID PHASE ASSAY COMPLEMENT FIXING ANTIBODIES 306/2018

DESPATCHED ON 13 NOVEMBER 2018

Complement fixing antibodies detected using solid phase assays - NOT ASSESSED

Consensus No specificities detected

% reported

Lab no.

24

114

136

162

273

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

Number 0

Total 5

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

SOLID PHASE ASSAY COMPLEMENT FIXING ANTIBODIES 307/2018

DESPATCHED ON 13 NOVEMBER 2018

Complement fixing antibodies detected using solid phase assays - NOT ASSESSED

Consensus No specificities detected
% reported

Lab no.

24

114

136

162

273

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

Number 0

Total 5

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

SOLID PHASE ASSAY COMPLEMENT FIXING ANTIBODIES 308/2018

DESPATCHED ON 13 NOVEMBER 2018

Complement fixing antibodies detected using solid phase assays - NOT ASSESSED

	A25	A26	A34	A66	A29	A33	A43	B8	B44	B13	B64	B65	B63	B54	B37	B60	B42
Consent	Present	Present	Present	Present	Not Assesse	Not Assesse	Present	Not Assesse	Not Assesse	Not Assesse	Not Assesse	Not Assesse	Not Assesse	Not Assesse	Present	Not Assesse	Not Assesse
% reporte	100.0%	100.0%	100.0%	100.0%	60.0%	60.0%	100.0%	60.0%	20.0%	20.0%	20.0%	20.0%	20.0%	20.0%	100.0%	20.0%	60.0%
Lab no.	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec
24	A25	A26	A34	A66	A29	A33	A43	B8							B37		B42
114	A25	A26	A34	A66			A43								B37		
136	A25	A26	A34	A66			A43								B37		
162	A25	A26	A34	A66	A29	A33	A43	B8	B44	B13	B64	B65	B63	B54	B37	B60	B42
273	A25	A26	A34	A66	A29	A33	A43	B8							B37		B42

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

Number	5	5	5	5	3	3	5	3	1	1	1	1	1	1	5	1	3
Total	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

B53	B73	Cw6	DR103	DR16	DR17	DR18	DR4	DR11	DR12	DR13	DR14	DR8	DR51	DR52	DQ5	DQ6	DQ4
Not Assessec	Not Assessec	Not Assessec	Present	Not Assessec	Present	Present	Present	Present	Present	Present	Present	Present	Not Assessec	Present	Present	Present	Present
40.0%	40.0%	40.0%	100.0%	60.0%	100.0%	100.0%	80.0%	100.0%	100.0%	100.0%	100.0%	100.0%	40.0%	100.0%	100.0%	100.0%	100.0%
spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec
			DR103	DR16	DR17	DR18	DR4	DR11	DR12	DR13	DR14	DR8		DR52	DQ5	DQ6	DQ4
			DR103		DR17	DR18	DR4	DR11	DR12	DR13	DR14	DR8		DR52	DQ5	DQ6	DQ4
			DR103		DR17	DR18		DR11	DR12	DR13	DR14	DR8		DR52	DQ5	DQ6	DQ4
B53	B73	Cw6	DR103	DR16	DR17	DR18	DR4	DR11	DR12	DR13	DR14	DR8	DR51	DR52	DQ5	DQ6	DQ4
B53	B73	Cw6	DR103	DR16	DR17	DR18	DR4	DR11	DR12	DR13	DR14	DR8	DR51	DR52	DQ5	DQ6	DQ4
2	2	2	5	3	5	5	4	5	5	5	5	5	2	5	5	5	5
5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

SOLID PHASE ASSAY COMPLEMENT FIXING ANTIBODIES 309/2018

DESPATCHED ON 13 NOVEMBER 2018

Complement fixing antibodies detected using solid phase assays - NOT ASSESSED

Consensus No specificities detected
% reported

Lab no.

24

114

136

162

273

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

Number

Total number of

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

SOLID PHASE ASSAY COMPLEMENT FIXING ANTIBODIES 310/2018

DESPATCHED ON 13 NOVEMBER 2018

Complement fixing antibodies detected using solid phase assays - NOT ASSESSED

	B8	B44	B13	B64	B63	B38	B39	B58	B54	B37	B60	B46
Consensus	Not Assessed	Not Assessed	Not Assessed	Not Assessed	Not Assessed	Not Assessed	Not Assessed	Not Assessed	Not Assessed	Not Assessed	Not Assessed	Present
% reported	20.0%	20.0%	20.0%	20.0%	20.0%	60.0%	60.0%	20.0%	20.0%	20.0%	20.0%	100.0%
Lab no.	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec
24						B38	B39					B46
114												B46
136												B46
162	B8	B44	B13	B64	B63	B38	B39	B58	B54	B37	B60	B46
273						B38	B39					B46

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

Number	1	1	1	1	1	3	3	1	1	1	1	5
Total	5	5	5	5	5	5	5	5	5	5	5	5

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

B53 Not Assessec 20.0%	B67 Not Assessec 60.0%	B73 Present 100.0%	Cw1 Present 80.0%	Cw9 Present 100.0%	Cw10 Present 100.0%	Cw6 Not Assessec 20.0%	Cw7 Present 100.0%	Cw8 Present 100.0%	Cw12 Present 100.0%	Cw14 Present 80.0%	Cw16 Not Assessec 60.0%	Cw18 Not Assessec 20.0%
spec	spec B67	spec B73 B73 B73	spec Cw1 Cw1	spec Cw9 Cw9 Cw9	spec Cw10 Cw10 Cw10	spec	spec Cw7 Cw7 Cw7	spec Cw8 Cw8 Cw8	spec Cw12 Cw12 Cw12	spec Cw14 Cw14	spec Cw16	spec
B53	B67 B67	B73 B73	Cw1 Cw1	Cw9 Cw9	Cw10 Cw10	Cw6	Cw7 Cw7	Cw8 Cw8	Cw12 Cw12	Cw14 Cw14	Cw16 Cw16	Cw18
1 5	3 5	5 5	4 5	5 5	5 5	1 5	5 5	5 5	5 5	4 5	3 5	1 5

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

SOLID PHASE ASSAY COMPLEMENT FIXING ANTIBODIES 306/2018

DESPATCHED ON 13 NOVEMBER 2018

Unacceptable antigen listing - NOT ASSESSED

Con sens us	A23	A24	A2403	A32	B51	B5102	B5103	B52	B62	B63	B77	B49	B50	B4005	B37	B59	B71	B78	Cw9	Cw10	Cw17	DR4	DR7	DR9	DR53
% reporte	Not Assessed	Not Assessed	Not Assessed	Absent	Present	Not Assessed	Not Assessed	Present	Not Assessed	Not Assessed	Not Assessed	Not Assessed	Absent	Absent	Not Assessed	Not Assessed	Absent	Not Assessed	Not Assessed	Not Assessed	Absent	Not Assessed	Not Assessed	Not Assessed	Present
Lab no.	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec
11					B51	B5102		B52				B49			B37										DR53
14					B51			B52																	DR53
19	A23	A24	A2403		B51			B52		B63	B77	B49			B37			B78							DR53
20					B51			B52				B49			B37										DR53
23					B51	B5102	B5103	B52		B63		B49	B50	B4005											DR53
24	A23				B51			B52		B63	B77	B49			B37			B78	Cw9						DR53
41					B51			B52		B63		B49			B37										DR53
58	A23	A24		A32	B51			B52	B62	B63	B77	B49			B37	B59	B71	B78	Cw9	Cw10	Cw17				DR53
62					B51			B52							B37										DR53
112								B52																	DR53
114	A23	A24	A2403		B51	B5102		B52	B62	B63	B77	B49			B37	B59		B78	Cw9						DR53
117	A23				B51			B52		B63		B49			B37			B78	Cw9						DR53
119	A23				B51	B5102		B52		B63		B49			B37										DR53
120					B51			B52				B49													DR53
133																									DR53
145					B51			B52		B63		B49													DR53
149								B52																	DR53
162					B51			B52		B63		B49													DR53
185								B52																	DR53
194	A23				B51	B5102	B5103	B52		B63		B49			B37							DR4	DR7	DR9	DR53
195	A23				B51			B52		B63		B49			B37			B78	Cw9			DR4	DR7	DR9	DR53
206																									DR53
232					B51			B52		B63		B49			B37				Cw9	Cw10					DR53
284	A23				B51			B52		B63		B49			B37							DR4	DR7	DR9	DR53
361																									DR53

DPB1*28:01

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

Number	9	3	2	1	19	5	2	21	2	14	4	17	1	1	14	2	1	6	6	2	1	3	3	3	20
Total	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

SOLID PHASE ASSAY COMPLEMENT FIXING ANTIBODIES 302/2018

DESPATCHED ON 13 NOVEMBER 2018

Unacceptable antigen listing - NOT ASSESSED

Consensus % reported	A24	A2403	A25	A26	A34	A66	A29	A30	A31	A33	A68	A43	B7	B703	B8	B44	B45	B64
Lab no.	Not Assessed	Not Assessed	Absent	Absent	Not Assessed	Not Assessed	Not Assessed	Absent	Not Assessed	Not Assessed	Not Assessed	Not Assessed	Not Assessed	Not Assessed	Not Assessed	Absent	Present	Not Assessed
11	12.0%	12.0%	4.0%	4.0%	16.0%	12.0%	12.0%	4.0%	12.0%	12.0%	16.0%	12.0%	64.0%	8.0%	20.0%	4.0%	76.0%	44.0%
	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec
14																		
19	A24	A2403			A34		A29		A31	A33	A68	A43	B7		B8		B45	B64
20													B7				B45	
23													B7	B703		B44	B45	B64
24													B7		B8		B45	B64
41													B7				B45	B64
58	A24		A25	A26	A34	A66	A29	A30	A31	A33	A68	A43	B7		B8		B45	B64
62																	B45	
112																		
114	A24	A2403			A34	A66	A29		A31	A33	A68	A43	B7		B8		B45	B64
117													B7				B45	B64
119													B7				B45	
120													B7				B45	
133																		
145													B7				B45	B64
149																	B45	
162					A34								B7				B45	B64
185																		
194													B7	B703			B45	B64
195																	B45	
206																		
232													B7				B45	
284													B7		B8		B45	B64
361		A2403				A66					A68							

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

Number	3	3	1	1	4	3	3	1	3	3	4	3	16	2	5	1	19	11
Total	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

B65 Not Assessed 12.0%	B62 Present 76.0%	B63 Absent 4.0%	B75 Not Assessed 72.0%	B76 Present 80.0%	B77 Absent 4.0%	B38 Absent 4.0%	B39 Not Assessed 60.0%	B3901 Not Assessed 24.0%	B3902 Not Assessed 8.0%	B18 Not Assessed 68.0%	B49 Absent 4.0%	B50 Not Assessed 64.0%	B4005 Absent 4.0%	B54 Not Assessed 64.0%	B55 Not Assessed 64.0%	B56 Not Assessed 64.0%	B27 Not Assessed 28.0%	B2708 Not Assessed 40.0%
spec	spec B62	spec	spec B75	spec B76	spec	spec	spec B39	spec B3901	spec	spec B18	spec	spec B50	spec	spec B54	spec B55	spec B56	spec B27	spec B2708
	B62		B75	B76			B39			B18		B50		B54	B55	B56		
B65	B62	B63	B75	B76	B77	B38	B39	B3901	B3902	B18	B49	B50	B4005	B54	B55	B56	B27	B2708
	B62		B75	B76			B39			B18		B50		B54	B55	B56		B2708
B65	B62		B75	B76			B39	B3901		B18		B50		B54	B55	B56	B27	B2708
	B62		B75	B76			B39			B18		B50		B54	B55	B56		B2708
B65	B62		B75	B76			B39	B3901		B18		B50		B54	B55	B56	B27	B2708
	B62		B75	B76			B39			B18		B50		B54	B55	B56		B2708
	B62		B75	B76			B39			B18		B50		B54	B55	B56		B2708
	B62		B75	B76			B39	B3901	B3902	B18		B50		B54	B55	B56		B2708
	B62		B75	B76			B39			B18		B50		B54	B55	B56	B27	
	B62		B75	B76			B39			B18		B50		B54	B55	B56		B2708
3	19	1	18	20	1	1	15	6	2	17	1	16	1	16	16	16	7	10
25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

B35 Not Assessed 64.0%	B60 Not Assessed 64.0%	B61 Not Assessed 64.0%	B41 Not Assessed 68.0%	B42 Not Assessed 64.0%	B46 Not Assessed 20.0%	B48 Not Assessed 64.0%	B67 Not Assessed 64.0%	B71 Not Assessed 68.0%	B72 Present 76.0%	B73 Absent 4.0%	B78 Not Assessed 64.0%	B81 Not Assessed 60.0%	B82 Not Assessed 16.0%	Cw9 Not Assessed 16.0%	Cw10 Not Assessed 8.0%	DR15 Not Assessed 24.0%
spec B35	spec B60	spec B61	spec B41	spec B42	spec	spec B48	spec B67	spec B71	spec B72	spec	spec B78	spec	spec	spec	spec	spec
B35	B60	B61	B41	B42	B46	B48	B67	B71	B72		B78	B81	B82	Cw9	Cw10	DR15
B35	B60	B61	B41	B42		B48	B67	B71	B72		B78	B81	B82			
B35	B60	B61	B41	B42		B48	B67	B71	B72		B78	B81				
B35	B60	B61	B41	B42	B46	B48	B67	B71	B72		B78	B81		Cw9		DR15
B35	B60	B61	B41	B42	B46	B48	B67	B71	B72		B78	B81		Cw9	Cw10	DR15
									B72	B73	B78	B81	B82			
									B72							
B35	B60	B61	B41	B42	B46	B48	B67	B71	B72		B78	B81	B82	Cw9		DR15
B35	B60	B61	B41	B42	B46	B48	B67	B71	B72		B78	B81				DR15
B35	B60	B61	B41	B42		B48	B67	B71	B72		B78	B81				
B35	B60	B61	B41	B42		B48	B67	B71	B72		B78	B81				
B35	B60	B61	B41	B42		B48	B67	B71	B72		B78	B81				
B35	B60	B61	B41	B42		B48	B67	B71	B72		B78	B81				
B35	B60	B61	B41	B42		B48	B67	B71	B72		B78	B81				
B35	B60	B61	B41	B42		B48	B67	B71	B72		B78	B81				DR15
B35	B60	B61	B41	B42		B48	B67	B71	B72		B78	B81				
16	16	16	17	16	5	16	16	17	19	1	16	15	4	4	2	6
25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

DR16 Not Assessed 16.0%	DR17 Present 92.0%	DR18 Present 92.0%	DR11 Present 92.0%	DR12 Present 84.0%	DR13 Present 92.0%	DR14 Present 92.0%	DR1403 Not Assessed 20.0%	DR1404 Not Assessed 20.0%	DR7 Not Assessed 24.0%	DR8 Present 88.0%	DR9 Not Assessed 36.0%	DR52 Present 80.0%	DQ2 Not Assessed 72.0%
spec	spec DR17	spec DR18	spec DR11	spec DR12	spec DR13	spec DR14	spec	spec	spec	spec DR8	spec	spec DR52	spec DQ2
	DR17	DR18	DR11		DR13	DR14				DR8		DR52	DQ2
DR16	DR17	DR18	DR11	DR12	DR13	DR14			DR7	DR8	DR9	DR52	DQ2
	DR17	DR18	DR11		DR13	DR14				DR8		DR52	DQ2
	DR17	DR18	DR11	DR12	DR13	DR14	DR1403	DR1404		DR8		DR52	DQ2
DR16	DR17	DR18	DR11	DR12	DR13	DR14			DR7	DR8	DR9	DR52	DQ2
	DR17	DR18	DR11	DR12	DR13	DR14				DR8		DR52	DQ2
DR16	DR17	DR18	DR11	DR12	DR13	DR14			DR7	DR8	DR9	DR52	DQ2
	DR17	DR18	DR11	DR12	DR13	DR14				DR8		DR52	DQ2
DR16	DR17	DR18	DR11	DR12	DR13	DR14	DR1403	DR1404		DR8		DR52	DQ2
	DR17	DR18	DR11	DR12	DR13	DR14			DR7	DR8	DR9	DR52	DQ2
	DR17	DR18	DR11	DR12	DR13	DR14			DR7	DR8	DR9	DR52	DQ2
	DR17	DR18	DR11	DR12	DR13	DR14				DR8		DR52	DQ2
	DR17	DR18	DR11	DR12	DR13	DR14				DR8		DR52	DQ2
	DR17	DR18	DR11	DR12	DR13	DR14	DR1403	DR1404		DR8		DR52	DQ2
	DR17	DR18	DR11	DR12	DR13	DR14				DR8	DR9		DQ2
	DR17	DR18	DR11	DR12	DR13	DR14	DR1403	DR1404		DR8		DR52	DQ2
	DR17	DR18	DR11	DR12	DR13	DR14	DR1403	DR1404		DR8		DR52	DQ2
	DR17	DR18	DR11	DR12	DR13	DR14				DR8	DR9	DR52	DQ2
	DR17	DR18	DR11	DR12	DR13	DR14				DR8	DR9	DR52	DQ2
	DR17	DR18	DR11	DR12	DR13	DR14			DR7	DR8	DR9	DR52	DQ2
	DR17	DR18	DR11	DR12	DR13	DR14				DR8	DR9	DR52	DQ2

DRB1*04:02 not listed as unacceptable, rare allele in caucasians

4	23	23	23	21	23	23	5	5	6	22	9	20	18
25	25	25	25	25	25	25	25	25	25	25	25	25	25

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

SOLID PHASE ASSAY COMPLEMENT FIXING ANTIBODIES 303/2018

DESPATCHED ON 13 NOVEMBER 2018

Unacceptable antigen listing - NOT ASSESSED

Consensus % reported	A1 Present 84.0%	A2 Not Assessed 8.0%	A203 Absent 4.0%	A3 Not Assessed 68.0%	A24 Not Assessed 12.0%	A2403 Not Assessed 12.0%	A25 Present 92.0%	A26 Present 92.0%	A34 Present 92.0%	A66 Present 92.0%	A11 Present 88.0%	A29 Present 92.0%	A30 Present 88.0%	A31 Present 84.0%	A32 Present 84.0%	A33 Present 92.0%	A74 Present 88.0%
Lab no.	spec A1	spec	spec	spec A3	spec	spec	spec A25	spec A26	spec A34	spec A66	spec A11	spec A29	spec A30	spec A31	spec A32	spec A33	spec A74
11	A1			A3			A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74
14	A1						A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74
19	A1			A3			A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74
20	A1			A3			A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74
23	A1			A3			A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74
24	A1			A3			A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74
41	A1			A3			A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74
58	A1	A2	A203	A3	A24		A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74
62	A1			A3			A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74
112	A1						A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74
114	A1	A2		A3	A24	A2403	A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74
117	A1			A3	A24		A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74
119	A1						A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74
120	A1			A3			A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74
133							A25	A26	A34	A66	A11	A29				A33	A74
145	A1			A3			A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74
149							A25	A26	A34	A66		A29	A30			A33	
162	A1			A3			A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74
185	A1						A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74
194	A1			A3			A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74
195	A1			A3		A2403	A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74
206																	
232	A1			A3			A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74
284	A1			A3		A2403	A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74
361																	

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

Number	21	2	1	17	3	3	23	23	23	23	22	23	22	21	21	23	22
Total	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

DR12 Present 92.0%	DR13 Present 92.0%	DR14 Present 92.0%	DR1403 Not Assessed 20.0%	DR1404 Not Assessed 20.0%	DR8 Present 92.0%	DR51 Not Assessed 72.0%	DR52 Present 80.0%	DQ5 Present 88.0%	DQ6 Present 92.0%	DQ2 Not Assessed 8.0%	DQ7 Absent 4.0%	DQ4 Present 92.0%	Others
spec	spec	spec	spec	spec	spec	spec	spec	spec	spec			spec	
DR12	DR13	DR14			DR8	DR51	DR52	DQ5	DQ6			DQ4	
DR12	DR13	DR14			DR8	DR51	DR52	DQ5	DQ6			DQ4	
DR12	DR13	DR14			DR8	DR51	DR52	DQ5	DQ6			DQ4	DP2, DP10, DP18, DP28
DR12	DR13	DR14	DR1403	DR1404	DR8	DR51	DR52	DQ5	DQ6			DQ4	
DR12	DR13	DR14			DR8	DR51	DR52	DQ5	DQ6			DQ4	DP2, DPB1*04:02, DP10, DP18, DP28
DR12	DR13	DR14			DR8	DR51	DR52	DQ5	DQ6			DQ4	DP2, DPB1*04:02, DP10, DP18, DP28, DQA1*05
DR12	DR13	DR14			DR8	DR51	DR52	DQ5	DQ6			DQ4	
DR12	DR13	DR14	DR1403	DR1404	DR8	DR51	DR52	DQ5	DQ6			DQ4	DPB1*02:01, 04:02, 18:01, 28:01
DR12	DR13	DR14			DR8	DR51	DR52	DQ5	DQ6			DQ4	
DR12	DR13	DR14			DR8	DR51	DR52	DQ5	DQ6			DQ4	DRB1*04:02, DRB5*01:01, DP18, 4, 2, 28, 10
DR12	DR13	DR14			DR8	DR51	DR52	DQ5	DQ6			DQ4	
DR12	DR13	DR14	DR1403	DR1404	DR8	DR51	DR52	DQ5	DQ6			DQ4	
DR12	DR13	DR14			DR8	DR51	DR52	DQ5	DQ6			DQ4	DRB1*04:02, Epitopes 56EE, DPB1*28:01, 04:02, 02:01, 18:01
DR12	DR13	DR14	DR1403	DR1404	DR8	DR51	DR52	DQ5	DQ6			DQ4	DRB1*04:02, DPB1*04:02, DP2, 28, 18, 10
DR12	DR13	DR14			DR8	DR51	DR52	DQ5	DQ6			DQ4	
DR12	DR13	DR14			DR8	DR51	DR52	DQ5	DQ6			DQ4	
DR12	DR13	DR14			DR8	DR51	DR52	DQ5	DQ6	DQ2	DQ7	DQ4	
DR12	DR13	DR14			DR8	DR51	DR52	DQ5	DQ6	DQ2		DQ4	
23	23	23	5	5	23	18	20	22	23	2	1	23	
25	25	25	25	25	25	25	25	25	25	25	25	25	

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

SOLID PHASE ASSAY COMPLEMENT FIXING ANTIBODIES 304/2018

DESPATCHED ON 13 NOVEMBER 2018

Unacceptable antigen listing - NOT ASSESSED

Lab no.	A25 Consens. % reported 4.0%	A33 Not Assessed 8.0%	B51 Present 84.0%	B5102 Not Assessed 28.0%	B5103 Not Assessed 8.0%	B52 Present 84.0%	B7 Not Assessed 32.0%	B8 Not Assessed 68.0%	B13 Not Assessed 64.0%	B64 Not Assessed 16.0%	B65 Not Assessed 12.0%	B62 Not Assessed 56.0%	B63 Present 84.0%	B75 Present 84.0%	B76 Not Assessed 12.0%	B77 Present 80.0%
spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec
11			B51	B5102		B52		B8	B13				B63	B75		B77
14			B51	B5102		B52							B63	B75		B77
19			B51			B52	B7	B8	B13	B64	B65	B62	B63	B75		B77
20			B51			B52		B8	B13			B62	B63	B75		B77
23			B51	B5102	B5103	B52		B8	B13			B62	B63	B75	B76	B77
24			B51			B52	B7	B8	B13	B64		B62	B63	B75		B77
41			B51			B52		B8	B13			B62	B63	B75		B77
58	A25	A33	B51			B52	B7	B8	B13	B64	B65	B62	B63	B75	B76	B77
62			B51			B52							B63	B75		B77
112			B51			B52							B63	B75		B77
114		A33	B51	B5102		B52	B7	B8	B13	B64	B65	B62	B63	B75	B76	B77
117			B51	B5102		B52	B7	B8	B13			B62	B63	B75		B77
119			B51	B5102		B52		B8	B13				B63	B75		B77
120			B51			B52		B8	B13			B62	B63	B75		B77
133																
145			B51			B52		B8	B13				B63	B75		B77
149			B51			B52							B63	B75		B77
162			B51			B52	B7	B8	B13			B62	B63	B75		B77
185																
194			B51	B5102	B5103	B52		B8				B62	B63	B75		B77
195			B51			B52	B7	B8	B13			B62	B63	B75		B77
206																
232			B51			B52	B7	B8	B13			B62	B63	B75		B77
284			B51			B52		B8	B13			B62	B63	B75		B77
361																

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

Number	1	2	21	7	2	21	8	17	16	4	3	14	21	21	3	20
Total	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

B41 Not Assessed 60.0%	B42 Not Assessed 60.0%	B46 Not Assessed 40.0%	B48 Not Assessed 72.0%	B53 Present 80.0%	B59 Not Assessed 60.0%	B67 Not Assessed 72.0%	B71 Present 84.0%	B72 Not Assessed 36.0%	B73 Not Assessed 8.0%	B78 Present 80.0%	B81 Not Assessed 60.0%	B82 Not Assessed 24.0%	Cw15 Not Assessed 28.0%	Cw17 Absent 4.0%	DR7 Absent 4.0%
spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec
			B48	B53		B67	B71			B78					
			B48	B53		B67	B71			B78					
B41	B42	B46	B48	B53	B59	B67	B71	B72		B78	B81	B82	Cw15		
B41	B42		B48	B53	B59	B67	B71			B78	B81				
B41	B42		B48	B53	B59	B67	B71	B72		B78	B81		Cw15		
B41	B42	B46	B48	B53	B59	B67	B71	B72		B78	B81	B82	Cw15		
B41	B42	B46	B48	B53	B59	B67	B71	B72	B73	B78	B81	B82	Cw15	Cw17	DR7
			B48	B53		B67	B71			B78					
			B48	B53		B67	B71			B78					
B41	B42	B46	B48	B53	B59	B67	B71	B72	B73	B78	B81	B82	Cw15		
B41	B42	B46	B48	B53	B59	B67	B71	B72		B78	B81	B82			
B41	B42		B48	B53	B59	B67	B71			B78	B81				
B41	B42	B46	B48	B53	B59	B67	B71	B72		B78	B81				
B41	B42	B46	B48	B53	B59	B67	B71	B72		B78	B81	B82			
B41	B42	B46	B48	B53	B59	B67	B71	B72		B78	B81		Cw15		
B41	B42	B46	B48	B53	B59	B67	B71	B72		B78	B81		Cw15		
15	15	10	18	20	15	18	21	9	2	20	15	6	7	1	1
25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

SOLID PHASE ASSAY COMPLEMENT FIXING ANTIBODIES 305/2018

DESPATCHED ON 13 NOVEMBER 2018

Unacceptable antigen listing - NOT ASSESSED																									
Lab no.	A1 Consensu. % reporte	A2 Absent 4.0%	A203 Not Assessed 24.0%	A210 Not Assessed 8.0%	A3 Not Assessed 32.0%	A23 Not Assessed 60.0%	A24 Not Assessed 64.0%	A2403 Not Assessed 28.0%	A25 Not Assessed 40.0%	A26 Absent 4.0%	A34 Not Assessed 56.0%	A66 Not Assessed 12.0%	A11 Not Assessed 8.0%	A29 Absent 4.0%	A30 Absent 4.0%	A31 Not Assessed 8.0%	A32 Not Assessed 44.0%	A33 Not Assessed 52.0%	A74 Absent 4.0%	A68 Not Assessed 72.0%	A69 Not Assessed 68.0%	A80 Not Assessed 16.0%	B51 Not Assessed 56.0%	B5102 Not Assessed 16.0%	B5103 Not Assessed 8.0%
	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec
11																									
14		A2	A203			A23	A24	A2403			A34									A68	A69		B51		
19																									
20		A2				A23	A24	A2403			A34						A32	A33		A68	A69		B51		
23		A2	A203	A210	A3	A23	A24	A2403	A25	A26	A34	A66	A11	A29	A30	A31	A32	A33	A74	A68	A69		B51	B5102	B5103
24																									
41		A2			A3	A23	A24		A25		A34						A32	A33		A68	A69		B51		
58																									
62		A2				A23	A24														A68	A69			
112		A2	A203			A23	A24	A2403													A68	A69			
114	A1	A2	A203		A3	A23	A24	A2403	A25		A34	A66	A11			A31	A32	A33		A68	A69	A80	B51	B5102	
117		A2			A3	A23	A24		A25		A34	A66					A32	A33		A68	A69	A80	B51		
119		A2																			A68	A69			
120		A2			A3	A23	A24		A25		A34						A32	A33		A68	A69		B51		
133		A2																			A68	A69			
145		A2				A23	A24				A34								A33		A68	A69		B51	
149																									
162		A2			A3	A23	A24		A25		A34						A32	A33		A68	A69	A80	B51		
185																									
194		A2	A203	A210		A23	A24	A2403	A25		A34						A32	A33		A68	A69		B51	B5102	B5103
195		A2				A23	A24		A25		A34						A32	A33		A68	A69		B51		
206																									
232		A2			A3	A23	A24		A25		A34						A32	A33		A68	A69		B51		
284		A2			A3	A23	A24		A25		A34						A32	A33		A68	A69	A80	B51		
361																									

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

Number	1	18	6	2	8	15	16	7	10	1	14	3	2	1	1	2	11	13	1	18	17	4	14	4	2
Total	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

B4005 Absent 4.0%	B54 Present 76.0%	B55 Present 76.0%	B56 Not Assessed 60.0%	B27 Not Assessed 68.0%	B2708 Not Assessed 44.0%	B35 Not Assessed 24.0%	B37 Not Assessed 64.0%	B60 Not Assessed 68.0%	B61 Not Assessed 60.0%	B41 Not Assessed 68.0%	B42 Present 76.0%	B46 Present 76.0%	B47 Not Assessed 20.0%	B48 Not Assessed 60.0%	B53 Not Assessed 24.0%	B59 Not Assessed 68.0%	B67 Present 76.0%	B71 Absent 4.0%	B72 Absent 4.0%	B73 Present 76.0%	B78 Not Assessed 44.0%	B81 Not Assessed 72.0%	B82 Not Assessed 72.0%
spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec
B54	B54	B55	B56	B27	B2708	B35	B37	B60	B61	B41	B42	B46	B47	B48	B53	B59	B67	B71	B72	B73	B78	B81	B82
	B54	B55	B56	B27	B2708		B37	B60	B61	B41	B42	B46		B48		B59	B67			B73		B81	B82
B4005	B54	B55	B56	B27	B2708	B35	B37	B60	B61	B41	B42	B46		B48	B53	B59	B67			B73	B78	B81	B82
	B54	B55	B56	B27	B2708		B37	B60	B61	B41	B42	B46		B48		B59	B67			B73	B78	B81	B82
	B54	B55	B56	B27	B2708		B37	B60	B61	B41	B42	B46		B48		B59	B67			B73		B81	B82
	B54	B55	B56	B27	B2708		B37	B60	B61	B41	B42	B46		B48		B59	B67			B73		B81	B82
	B54	B55	B56	B27	B2708	B35	B37	B60	B61	B41	B42	B46	B47	B48	B53	B59	B67	B71	B72	B73	B78	B81	B82
	B54	B55	B56	B27	B2708	B35	B37	B60	B61	B41	B42	B46	B47	B48	B53	B59	B67			B73	B78	B81	B82
	B54	B55	B56	B27	B2708		B37	B60	B61	B41	B42	B46		B48		B59	B67			B73		B81	B82
	B54	B55	B56	B27	B2708		B37	B60	B61	B41	B42	B46		B48		B59	B67			B73		B81	B82
	B54	B55	B56	B27	B2708	B35	B37	B60	B61	B41	B42	B46	B47	B48	B53	B59	B67			B73	B78	B81	B82
	B54	B55	B56	B27	B2708		B37	B60	B61	B41	B42	B46		B48		B59	B67			B73	B78	B81	B82
	B54	B55	B56	B27	B2708		B37	B60	B61	B41	B42	B46		B48		B59	B67			B73	B78	B81	B82
	B54	B55	B56	B27	B2708	B35	B37	B60	B61	B41	B42	B46	B47	B48	B53	B59	B67			B73	B78	B81	B82
	B54	B55	B56	B27	B2708		B37	B60	B61	B41	B42	B46		B48		B59	B67			B73	B78	B81	B82
	B54	B55	B56	B27	B2708	B35	B37	B60	B61	B41	B42	B46	B47	B48	B53	B59	B67			B73	B78	B81	B82
	B54	B55	B56	B27	B2708		B37	B60	B61	B41	B42	B46		B48		B59	B67			B73	B78	B81	B82
1	19	19	15	17	11	6	16	17	15	17	19	19	5	15	6	17	19	1	1	19	11	18	18
25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

Cw1 Not Assessed 68.0%	Cw2 Not Assessed 40.0%	Cw9 Not Assessed 68.0%	Cw10 Not Assessed 68.0%	Cw4 Not Assessed 20.0%	Cw5 Not Assessed 56.0%	Cw6 Not Assessed 56.0%	Cw7 Not Assessed 72.0%	Cw8 Not Assessed 68.0%	Cw12 Not Assessed 68.0%	Cw14 Not Assessed 68.0%	Cw15 Not Assessed 52.0%	Cw16 Not Assessed 60.0%	Cw17 Not Assessed 36.0%	Cw18 Not Assessed 44.0%	DR1 Not Assessed 60.0%	DR103 Not Assessed 56.0%	DR15 Not Assessed 60.0%	DR16 Not Assessed 60.0%	DR17 Not Assessed 60.0%	DR18 Not Assessed 64.0%	DR4 Not Assessed 64.0%
spec Cw1	spec	spec Cw9	spec Cw10	spec	spec Cw5	spec Cw6	spec Cw7	spec Cw8	spec Cw12	spec Cw14	spec Cw15	spec Cw16	spec	spec Cw18	spec	spec	spec	spec	spec	spec	spec
		Cw9	Cw10		Cw5	Cw6	Cw7	Cw8	Cw12	Cw14	Cw15	Cw16	Cw17	Cw18	DR1	DR103	DR15	DR16	DR17	DR18	DR4
Cw1	Cw2	Cw9	Cw10		Cw5	Cw6	Cw7	Cw8	Cw12	Cw14	Cw15	Cw16	Cw17	Cw18	DR1	DR103	DR15	DR16	DR17	DR18	DR4
Cw1	Cw2	Cw9	Cw10	Cw4	Cw5	Cw6	Cw7	Cw8	Cw12	Cw14	Cw15	Cw16	Cw17	Cw18	DR1	DR103	DR15	DR16	DR17	DR18	DR4
Cw1	Cw2	Cw9	Cw10		Cw5	Cw6	Cw7	Cw8	Cw12	Cw14	Cw15	Cw16	Cw17	Cw18	DR1	DR103	DR15	DR16	DR17	DR18	DR4
Cw1		Cw9	Cw10		Cw5	Cw6	Cw7	Cw8	Cw12	Cw14		Cw16	Cw17	Cw18	DR1	DR103	DR15	DR16	DR17	DR18	DR4
Cw1	Cw2	Cw9	Cw10	Cw4	Cw5	Cw6	Cw7	Cw8	Cw12	Cw14	Cw15	Cw16			DR1	DR103	DR15	DR16	DR17	DR18	DR4
Cw1		Cw9	Cw10		Cw5		Cw7	Cw8	Cw12	Cw14	Cw15				DR1	DR103	DR15	DR16	DR17	DR18	DR4
Cw1	Cw2	Cw9	Cw10		Cw5	Cw6	Cw7	Cw8	Cw12	Cw14	Cw15	Cw16	Cw17		DR1	DR103	DR15	DR16	DR17	DR18	DR4
Cw1		Cw9	Cw10		Cw5	Cw6	Cw7	Cw8	Cw12	Cw14		Cw16			DR1	DR103	DR15	DR16	DR17	DR18	DR4
Cw1	Cw2	Cw9	Cw10		Cw5	Cw6	Cw7	Cw8	Cw12	Cw14	Cw15	Cw16			DR1	DR103	DR15	DR16	DR17	DR18	DR4
Cw1	Cw2	Cw9	Cw10	Cw4	Cw5	Cw6	Cw7	Cw8	Cw12	Cw14	Cw15	Cw16	Cw17	Cw18	DR1	DR103	DR15	DR16	DR17	DR18	DR4
Cw1	Cw2	Cw9	Cw10	Cw4	Cw5	Cw6	Cw7	Cw8	Cw12	Cw14	Cw15	Cw16	Cw17	Cw18	DR1	DR103	DR15	DR16	DR17	DR18	DR4
17	10	17	17	5	14	14	18	17	17	17	13	15	9	11	15	14	15	15	15	16	16
25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

DR11 Not Assessed 64.0%	DR12 Not Assessed 60.0%	DR13 Not Assessed 64.0%	DR14 Not Assessed 64.0%	DR1403 Not Assessed 16.0%	DR1404 Not Assessed 12.0%	DR7 Not Assessed 52.0%	DR8 Not Assessed 60.0%	DR9 Not Assessed 60.0%	DR10 Not Assessed 60.0%	DR51 Not Assessed 52.0%	DR52 Not Assessed 52.0%	DR53 Not Assessed 48.0%	DQ5 Not Assessed 60.0%	DQ6 Not Assessed 60.0%	DQ7 Not Assessed 52.0%	DQ8 Not Assessed 48.0%	DQ9 Not Assessed 48.0%	DQ4 Not Assessed 48.0%	
spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	spec	
DR11	DR12	DR13	DR14			DR7	DR8	DR9	DR10	DR51	DR52	DR53	DQ5	DQ6	DQ7				All DRB1 and DRB3/4/5 antigens positive by Class II SABs, would require HLA type of patient prior to listing UAGs
DR11	DR12	DR13	DR14			DR7	DR8	DR9	DR10	DR51	DR52	DR53	DQ5	DQ6	DQ7	DQ8	DQ9	DQ4	Further work would be needed to look at 310 before listing all the specificities as unacceptable Can't call unacceptable antigens for 310 without HLA type as all HLA-B, C and DR antibodies positive
DR11	DR12	DR13	DR14	DR1403	DR1404	DR7	DR8	DR9	DR10	DR51	DR52	DR53	DQ5	DQ6	DQ7	DQ8	DQ9	DQ4	DP3, DPB1*04:02, DP6, DP10, DP18, DP19, DP20, DP28
DR11	DR12	DR13	DR14	DR1403	DR1404		DR8	DR9	DR10	DR51	DR52	DR53	DQ5	DQ6					310/2018 cannot be assessed clinically as HLA type unavailable
DR11	DR12	DR13	DR14	DR1403		DR7	DR8	DR9	DR10	DR51	DR52	DR53	DQ5	DQ6	DQ7	DQ8	DQ9	DQ4	310 should be studied extensively, typing patient (and previous donors) to understand the reactivity pattern
DR11	DR12	DR13	DR14				DR8	DR9	DR10	DR51	DR52		DQ5	DQ6					DP19
DR11	DR12	DR13	DR14			DR7	DR8	DR9	DR10	DR51	DR52	DR53	DQ5	DQ6	DQ7	DQ8	DQ9	DQ4	
DR11	DR12	DR13	DR14			DR7	DR8	DR9	DR10	DR51	DR52	DR53	DQ5	DQ6	DQ7	DQ8	DQ9	DQ4	
DR11	DR12	DR13	DR14	DR1403	DR1404	DR7	DR8	DR9	DR10	DR51	DR52	DR53	DQ5	DQ6	DQ7	DQ8	DQ9	DQ4	
DR11	DR12	DR13	DR14			DR7	DR8	DR9	DR10	DR51	DR52	DR53	DQ5	DQ6	DQ7	DQ8	DQ9	DQ4	
DR11	DR12	DR13	DR14			DR7	DR8	DR9	DR10	DR51	DR52	DR53	DQ5	DQ6	DQ7	DQ8	DQ9	DQ4	
16 25	15 25	16 25	16 25	4 25	3 25	13 25	15 25	15 25	15 25	13 25	13 25	12 25	15 25	15 25	13 25	12 25	12 25	12 25	